Nuclear medicine also known as radiopharmaceutical in which radioactive isotopes are used for the diagnosis and therapy for variety of diseases, such as cancer, heart diseases, gastrointestinal, endocrine, neurological disorders. Nuclear medicines are non-invasive in nature and contain specialty that includes the usage of radioactive isotopes in the diagnosis and in treatment of various diseases.
The global nuclear medicine market in 2020 is estimated for more than US$ 4.3 Bn and expected to reach a value of US$ 6.3 Bn by 2028 with a significant CAGR of 4.8%.
Nuclear Medicine Market Key Players
Global nuclear medicine market is mainly dominated by:
Siemens AG
Eckert & Ziegler
Lantheus Holdings, Inc.
Cardinal Health
Bayer AG
Bracco Imaging S.P.A.
Nordian Inc.
Advanced Accelerator Applications
Mallinckrodt plc.
In 2017, the Siemens AG is accounted as the most dominating player in the global nuclear medicine market by holding more than 40% of the global nuclear medicine market followed by GE healthcare and Mallinckrodt PLC
Nuclear Medicine Market Segmentation
The global nuclear medicine market is segmented on the basis of application, radioisotope, source, end user, and by region.
On the basis of application segment, the global nuclear medicine market is segmented into:
Oncology
Cardiology
Gastroenterology
Neuroendocrinology
Neurology
Nephrology
Others
In 2018, the oncology application segment is accounted to have the largest market share in terms of value and expected to remain to dominate throughout the forecast period (2019-2027).
Nuclear Medicine Market Dynamics
Evolution towards centralized pharmacies, widespread availability of the SPECT and PET scanning machines, the growing interest of investors of conventional pharmaceutical industries in the therapeutic area, increasing incidence of cancer and cardiovascular diseases are some of the factors that will drive the growth of the nuclear medicine market during the forecast period.
There has been a growing interest in the development of tracers for therapeutic indications during recent years. The increasing number of manufacturers and research organizations are focusing on introducing novel therapeutic radiopharmaceuticals in the market. For instance, in March 2016, Isotopen Technologien München (ITM) raised US$ 20.8 million to fund the clinical development of its promising proprietary pipeline of Targeted Radionuclide Therapies. Also, in May 2016, Clarity Pharmaceuticals, an early stage Australian company, was granted US$ 0.7 million by Federal Government’s in order to fast track the Phase IIa clinical trial of Cu-64 SARTATE, a neuroendocrine tumor imaging radiopharmaceutical.
Regional Segmentation Overview
On the basis of region, the global nuclear medicine market is segmented into six regions namely North America, Latin America, Asia Pacific, Europe, Middle East, and Africa. North America nuclear medicine market is expected to be the most dominating market throughout the forecast period. Availability of key players and increasing healthcare expenditure in the region are some of the revenue boosting factors.
1. Global Nuclear Medicine Market Report Overview
1.1. Introduction
1.2. Report Description
1.3. Methodology
2. Global Nuclear Medicine Market Overview
2.1. Introduction
2.1.1. Market Definition
2.1.2. Market Taxonomy
2.2. Executive Summary
2.3. Global Nuclear Medicine Market Snapshot
2.4. Global Nuclear Medicine Market Size and Forecast, 2019–2027
2.4.1. Introduction
2.4.2. Market Value Forecast and Annual Growth Rate (AGR) Comparison (2019–2027)
2.5. Global Nuclear Medicine Market Dynamics
2.5.1. Drivers
2.5.2. Restraints
2.5.3. Opportunity
2.5.4. Trends
2.6. Key Regulations
2.7. Porter’s Five Forces Model
3. Global Nuclear Medicine Market, By Application
3.1. Introduction
3.1.1. Annual Growth Rate Comparison, By Application
3.1.2. BPS Analysis, By Application
3.2. Market Revenue (US$Mn) Forecast, By Application
3.2.1. Oncology
3.2.2. Cardiology
3.2.3. Gastroenterology
3.2.4. Neuroendocrinology
3.2.5. Neurology
3.2.6. Nephrology
3.2.7. Others
3.3. Global Nuclear Medicine Market Attractiveness Index, By Application
4. Global Nuclear Medicine Market, By Radioisotope
4.1. Introduction
4.1.1. Annual Growth Rate Comparison, By Radioisotope
4.1.2. BPS Analysis, By Radioisotope
4.2. Market Revenue (US$Mn) Forecast, By Radioisotope
4.2.1. Tec. 99
4.2.2. F18
4.2.3. Iodine 131
4.2.4. Lutetium 177
4.2.5. Yttrium 90
4.2.6. Gallium 68
4.2.7. Gallium 67
4.2.8. Rubidium 82
4.2.9. Iodine 123
4.2.10. Iodine 125
4.2.11. Indium 111
4.2.12. Others
4.3. Global Nuclear Medicine Market Attractiveness Index, By Radioisotope
5. Global Nuclear Medicine Market, By Source
5.1. Introduction
5.1.1. Annual Growth Rate Comparison, By Source
5.1.2. BPS Analysis, By Source
5.2. Market Revenue (US$Mn) Forecast, By Source
5.2.1. Cyclotrons
5.2.2. Nuclear Reactors
5.3. Global Nuclear Medicine Market Attractiveness Index, By Source
6. Global Nuclear Medicine Market, By End User
6.1. Introduction
6.1.1. Annual Growth Rate Comparison, By End User
6.1.2. BPS Analysis, By End User
6.2. Market Revenue (US$Mn) Forecast, By End User
6.2.1. Hospitals
6.2.2. Diagnostic Imaging Centers
6.2.3. Ambulatory Surgical Centers
6.2.4. Cancer Research Institute
6.3. Global Nuclear Medicine Market Attractiveness Index, By End User
7. Global Nuclear Medicine Market, By Region
7.1. Introduction
7.1.1. Annual Growth Rate Comparison, By Region
7.1.2. BPS Analysis, By Region
7.2. Market Revenue (US$Mn) Forecast, By Region
7.2.1. North America
7.2.2. Latin America
7.2.3. Europe
7.2.4. Asia Pacific
7.2.5. Middle East
7.2.6. Africa
7.3. Global Nuclear Medicine Market Attractiveness Index, By Region
8. North America Nuclear Medicine Market Analysis and Forecast, 2019–2027
8.1. Introduction
8.1.1. Annual Growth Rate Comparison, By Country
8.1.2. BPS Analysis, By Country
8.2. Market Revenue (US$Mn) Forecast, By Country
8.2.1. U.S. Nuclear Medicine Market
8.2.2. Canada Nuclear Medicine Market
8.3. North America Nuclear Medicine Market, By Application
8.3.1. Oncology
8.3.2. Cardiology
8.3.3. Gastroenterology
8.3.4. Neuroendocrinology
8.3.5. Neurology
8.3.6. Nephrology
8.3.7. Others
8.4. North America Nuclear Medicine Market, By Radioisotope
8.4.1. Tec. 99
8.4.2. F18
8.4.3. Iodine 131
8.4.4. Lutetium 177
8.4.5. Yttrium 90
8.4.6. Gallium 68
8.4.7. Gallium 67
8.4.8. Rubidium 82
8.4.9. Iodine 123
8.4.10. Iodine 125
8.4.11. Indium 111
8.4.12. Others
8.5. North America Nuclear Medicine Market, By Source
8.5.1. Cyclotrons
8.5.2. Nuclear Reactors
8.6. North America Nuclear Medicine Market, By End User
8.6.1. Hospitals
8.6.2. Diagnostic Imaging Centers
8.6.3. Ambulatory Surgical Centers
8.6.4. Cancer Research Institute
8.7. North America Nuclear Medicine Market Attractiveness Index
8.7.1. By Country
8.7.2. By Application
8.7.3. By Radioisotope
8.7.4. By Source
8.7.5. By End User
9. Latin America Nuclear Medicine Market Analysis and Forecast, 2019–2027
9.1. Introduction
9.1.1. Annual Growth Rate Comparison, By Country
9.1.2. BPS Analysis, By Country
9.2. Market (US$Mn) Forecast, By Country
9.2.1. Brazil Nuclear Medicine Market
9.2.2. Mexico Nuclear Medicine Market
9.2.3. Argentina Nuclear Medicine Market
9.2.4. Rest of Latin America Nuclear Medicine Market
9.3. Latin America Nuclear Medicine Market, By Application
9.3.1. Oncology
9.3.2. Cardiology
9.3.3. Gastroenterology
9.3.4. Neuroendocrinology
9.3.5. Neurology
9.3.6. Nephrology
9.3.7. Others
9.4. Latin America Nuclear Medicine Market, By Radioisotope
9.4.1. Tec. 99
9.4.2. F18
9.4.3. Iodine 131
9.4.4. Lutetium 177
9.4.5. Yttrium 90
9.4.6. Gallium 68
9.4.7. Gallium 67
9.4.8. Rubidium 82
9.4.9. Iodine 123
9.4.10. Iodine 125
9.4.11. Indium 111
9.4.12. Others
9.5. Latin America Nuclear Medicine Market, By Source
9.5.1. Cyclotrons
9.5.2. Nuclear Reactors
9.6. Latin America Nuclear Medicine Market, By End User
9.6.1. Hospitals
9.6.2. Diagnostic Imaging Centers
9.6.3. Ambulatory Surgical Centers
9.6.4. Cancer Research Institute
9.7. Latin America Nuclear Medicine Market Attractiveness Index
9.7.1. By Country
9.7.2. By Application
9.7.3. By Radioisotope
9.7.4. By Source
9.7.5. By End User
10. Europe Nuclear Medicine Market Analysis and Forecast, 2019–2027
10.1. Introduction
10.1.1. Annual Growth Rate Comparison, By Country
10.1.2. BPS Analysis, By Country
10.2. Market (US$Mn) Forecast, By Country
10.2.1. U.K. Nuclear Medicine Market
10.2.2. Germany Nuclear Medicine Market
10.2.3. Italy Nuclear Medicine Market
10.2.4. France Nuclear Medicine Market
10.2.5. Spain Nuclear Medicine Market
10.2.6. Russia Nuclear Medicine Market
10.2.7. Poland Nuclear Medicine Market
10.2.8. BENELUX Nuclear Medicine Market
10.2.9. NORDIC Nuclear Medicine Market
10.2.10. Rest of Europe Nuclear Medicine Market
10.3. Europe Nuclear Medicine Market, By Application
10.3.1. Oncology
10.3.2. Cardiology
10.3.3. Gastroenterology
10.3.4. Neuroendocrinology
10.3.5. Neurology
10.3.6. Nephrology
10.3.7. Others
10.4. Europe Nuclear Medicine Market, By Radioisotope
10.4.1. Tec. 99
10.4.2. F18
10.4.3. Iodine 131
10.4.4. Lutetium 177
10.4.5. Yttrium 90
10.4.6. Gallium 68
10.4.7. Gallium 67
10.4.8. Rubidium 82
10.4.9. Iodine 123
10.4.10. Iodine 125
10.4.11. Indium 111
10.4.12. Others
10.5. Europe Nuclear Medicine Market, By Source
10.5.1. Cyclotrons
10.5.2. Nuclear Reactors
10.6. Europe Nuclear Medicine Market, By End User
10.6.1. Hospitals
10.6.2. Diagnostic Imaging Centers
10.6.3. Ambulatory Surgical Centers
10.6.4. Cancer Research Institute
10.7. Europe Nuclear Medicine Market Attractiveness Index
10.7.1. By Country
10.7.2. By Application
10.7.3. By Radioisotope
10.7.4. By Source
10.7.5. By End User
11. Asia Pacific Nuclear Medicine Market Analysis and Forecast, 2019–2027
11.1. Introduction
11.1.1. Annual Growth Rate Comparison, By Country
11.1.2. BPS Analysis, By Country
11.2. Market (US$Mn) Forecast, By Country
11.2.1. China Nuclear Medicine Market
11.2.2. India Nuclear Medicine Market
11.2.3. Japan Nuclear Medicine Market
11.2.4. Australia and New Zealand Nuclear Medicine Market
11.2.5. South Korea Nuclear Medicine Market
11.2.6. ASEAN Nuclear Medicine Market
11.2.7. Rest of Asia Pacific Nuclear Medicine Market
11.3. Asia Pacific Nuclear Medicine Market, By Application
11.3.1. Oncology
11.3.2. Cardiology
11.3.3. Gastroenterology
11.3.4. Neuroendocrinology
11.3.5. Neurology
11.3.6. Nephrology
11.3.7. Others
11.4. Asia Pacific Nuclear Medicine Market, By Radioisotope
11.4.1. Tec. 99
11.4.2. F18
11.4.3. Iodine 131
11.4.4. Lutetium 177
11.4.5. Yttrium 90
11.4.6. Gallium 68
11.4.7. Gallium 67
11.4.8. Rubidium 82
11.4.9. Iodine 123
11.4.10. Iodine 125
11.4.11. Indium 111
11.4.12. Others
11.5. Asia Pacific Nuclear Medicine Market, By Source
11.5.1. Cyclotrons
11.5.2. Nuclear Reactors
11.6. Asia Pacific Nuclear Medicine Market, By End User
11.6.1. Hospitals
11.6.2. Diagnostic Imaging Centers
11.6.3. Ambulatory Surgical Centers
11.6.4. Cancer Research Institute
11.7. Asia Pacific Nuclear Medicine Market Attractiveness Index
11.7.1. By Country
11.7.2. By Application
11.7.3. By Radioisotope
11.7.4. By Source
11.7.5. By End User
12. Middle East Nuclear Medicine Market, By Region
12.1. Introduction
12.1.1. Annual Growth Rate Comparison, By Country
12.1.2. BPS Analysis, By Country
12.2. Market (US$Mn) Forecast, By Country
12.2.1. GCC Countries Nuclear Medicine Market
12.2.2. Israel Nuclear Medicine Market
12.2.3. Oman Nuclear Medicine Market
12.2.4. Rest of Middle East Nuclear Medicine Market
12.3. Middle East Nuclear Medicine Market, By Application
12.3.1. Oncology
12.3.2. Cardiology
12.3.3. Gastroenterology
12.3.4. Neuroendocrinology
12.3.5. Neurology
12.3.6. Nephrology
12.3.7. Others
12.4. Middle East Nuclear Medicine Market, By Radioisotope
12.4.1. Tec. 99
12.4.2. F18
12.4.3. Iodine 131
12.4.4. Lutetium 177
12.4.5. Yttrium 90
12.4.6. Gallium 68
12.4.7. Gallium 67
12.4.8. Rubidium 82
12.4.9. Iodine 123
12.4.10. Iodine 125
12.4.11. Indium 111
12.4.12. Others
12.5. Middle East Nuclear Medicine Market, By Source
12.5.1. Cyclotrons
12.5.2. Nuclear Reactors
12.6. Middle East Nuclear Medicine Market, By End User
12.6.1. Hospitals
12.6.2. Diagnostic Imaging Centers
12.6.3. Ambulatory Surgical Centers
12.6.4. Cancer Research Institute
12.7. Middle East Nuclear Medicine Market Attractiveness Index
12.7.1. By Country
12.7.2. By Application
12.7.3. By Radioisotope
12.7.4. By Source
12.7.5. By End User
13. Africa Nuclear Medicine Market, By Region
13.1. Introduction
13.1.1. Annual Growth Rate Comparison, By Country
13.1.2. BPS Analysis, By Country
13.2. Market (US$Mn) Forecast, By Country
13.2.1. South Africa Nuclear Medicine Market
13.2.2. Egypt Nuclear Medicine Market
13.2.3. North Africa Nuclear Medicine Market
13.2.4. Rest of Africa Nuclear Medicine Market
13.3. Africa Nuclear Medicine Market, By Application
13.3.1. Oncology
13.3.2. Cardiology
13.3.3. Gastroenterology
13.3.4. Neuroendocrinology
13.3.5. Neurology
13.3.6. Nephrology
13.3.7. Others
13.4. Africa Nuclear Medicine Market, By Radioisotope
13.4.1. Tec. 99
13.4.2. F18
13.4.3. Iodine 131
13.4.4. Lutetium 177
13.4.5. Yttrium 90
13.4.6. Gallium 68
13.4.7. Gallium 67
13.4.8. Rubidium 82
13.4.9. Iodine 123
13.4.10. Iodine 125
13.4.11. Indium 111
13.4.12. Others
13.5. Africa Nuclear Medicine Market, By Source
13.5.1. Cyclotrons
13.5.2. Nuclear Reactors
13.6. Africa Nuclear Medicine Market, By End User
13.6.1. Hospitals
13.6.2. Diagnostic Imaging Centers
13.6.3. Ambulatory Surgical Centers
13.6.4. Cancer Research Institute
13.7. Africa Nuclear Medicine Market Attractiveness Index
13.7.1. By Country
13.7.2. By Application
13.7.3. By Radioisotope
13.7.4. By Source
13.7.5. By End User
14. Recommendation
14.1. Market Strategy
15. Competitive Landscape
15.1. Competition Dashboard
15.2. List and Company Overview of Global Key Players
15.3. Company Profiles
15.3.1. Siemens AG
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Key Developments
15.3.1.5. Business Strategies
15.3.2. Eckert & Ziegler
15.3.3. Lantheus Holdings, Inc.
15.3.4. Cardinal Health
15.3.5. Bayer AG
15.3.6. Bracco Imaging S.P.A.
15.3.7. Nordian Inc.
15.3.8. Advanced Accelerator Applications
15.3.9. Mallinckrodt plc
16. Acronyms
Frequently Asked Questions
What is the projected market size & Compound Annual Growth Rate (CAGR) of the market?
The global nuclear medicine market in 2020 is estimated for more than US$ 4.3 Bn and expected to reach a value of US$ 6.3 Bn by 2028 with a significant CAGR of 4.8%.
What are the key factors driving the growth of market?
Evolution towards centralized pharmacies, widespread availability of the SPECT and PET scanning machines, the growing interest of investors of conventional pharmaceutical industries in the therapeutic area, increasing incidence of cancer and cardiovascular diseases are some of the factors that will drive the growth of the nuclear medicine market
What segments are covered in market report?
The global nuclear medicine market is segmented on the basis of application, radioisotope, source, end user, and by region
What are the key participating players in the market?
Siemens AG, Eckert & Ziegler, Lantheus Holdings, Inc., Cardinal Health, Bayer AG, Bracco Imaging S.P.A., Nordian Inc., Advanced Accelerator Applications, Mallinckrodt plc are the key participating players in the market
